Omnicell, Inc.

NASDAQ:OMCL

Medical - Healthcare Information Services

Healthcare
$34.66 -1.49%

-$0.58 today

Market cap
$1.59B
Beta
0.96
P/E (TTM)
84.1
EPS (TTM)
$0.45
52W Low $26.85High $55.00

Volume 0.34M

Average 0.57M

OMCL Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Omnicell, Inc.NASDAQ: OMCL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $18.57M fell 15.0% year over year, behind the -5.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 14.7% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.

Context

  • Depreciation & amortization amounted to 7.3% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -15.0% toward the trailing-twelve-month pace of -5.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.57M-14.7% QoQ
Last fiscal yearDec 2025
$86.63M-3.5% YoY
LTMMar 2026
$83.36M-5.7% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.0%——
1 year-3.5%——
3-year CAGR-4.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
86.63M USD
Year-over-year change
-3.5%
4-year CAGR
+0.5%

Depreciation & Amortization vs competitors

How OMCL compares with its peers on the latest reported figures

  • OMCL's LTM Mar 2026 depreciation & amortization of $83.36M is the 3rd highest of the 11 companies compared; the peer median is $26.67M.
  • Its year-over-year change of -5.7% is the 9th highest of 11, against a peer median of +14.3%.
  • Depreciation & amortization amounts to 6.8% of revenue for OMCL, versus a peer median of 2.8%.
OMCL Competitors Peer median
Depreciation & Amortization for OMCL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$233.19M +6.2%+20.0%9.3%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$86.1M +15.6%+16.3%10.9%
OMCLOmnicell, Inc.LTM Mar 2026$83.36M -5.7%-4.4%6.8%
ASTHAstrana Health, Inc.LTM Mar 2026$54.38M +83.2%+37.6%1.5%
PHRPhreesia, Inc.LTM Apr 2026$34.65M +22.0%+3.0%7.0%
TXG10x Genomics, Inc.LTM Sep 2026$33.67M -20.4%+9.9%5.4%
UFPTUFP Technologies, Inc.LTM Jun 2026$19.66M +9.0%+17.2%3.1%
PGNYProgyny, Inc.LTM Jun 2026$7.22M +79.8%+45.7%0.6%
OMDAOmada HealthLTM Mar 2026$5.67M +13.1%+8.2%2.0%
SDGRSchrödinger, Inc.LTM Sep 2026$4.4M -30.7%+11.5%1.6%
SSIISS Innovations International, Inc.LTM Mar 2026$1.19M +43.1%+102.8%2.5%
Peer median (excluding OMCL) $26.67M+14.3%+16.8%2.8%

Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.13B1.3B1.15B1.11B1.18B
Cost of Revenue577.37M706.96M647.18M641.24M676.8M
Gross Profit554.65M588.99M499.93M471M508.04M
Gross Margin49.0%45.4%43.6%42.3%42.9%
Research & Development75.72M104.97M93.29M90.41M87.74M
Selling, General & Admin389.43M486.34M425.97M380.25M408.64M
Operating Expenses465.15M591.31M519.26M470.67M496.38M
Depreciation & Amortization84.93M99.17M95.56M89.76M86.63M
EBITDA173.33M96.85M79.98M119.87M101.87M
EBITDA Margin15.3%7.5%7.0%10.8%8.6%
Operating Income89.51M(2.32M)(19.33M)337K11.67M
Operating Margin7.9%-0.2%-1.7%0.0%1.0%
Interest Income0014.76M24.9M11.9M
Interest Expense22.39M130K04.53M3.91M
Other Income / Expenses(23.5M)(130K)(779K)25.26M(340K)
Income Before Tax66.01M(2.45M)(20.11M)25.59M11.33M
Pre-Tax Margin5.8%-0.2%-1.8%2.3%1.0%
Income Tax Expense(11.84M)(8.1M)263K13.06M9.27M
Net Income77.85M5.65M(20.37M)12.53M2.05M
Net Margin6.9%0.4%-1.8%1.1%0.2%
EPS (Basic)1.790.13(0.45)0.270.04
EPS (Diluted)1.620.12(0.45)0.270.04
Weighted Avg Shares43.48M44.4M45.21M46.05M45.97M
Weighted Avg Shares (Diluted)47.94M45.89M45.21M46.26M46.36M

Omnicell, Inc.

NASDAQ:OMCL

Intrinsic Alpha fair value

Locked

Current Price

$34.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.